284 related articles for article (PubMed ID: 28755185)
1. The Liver in Tyrosinemia Type I: Clinical Management and Course in Quebec.
Halac U; Dubois J; Mitchell GA
Adv Exp Med Biol; 2017; 959():75-83. PubMed ID: 28755185
[TBL] [Abstract][Full Text] [Related]
2. The Québec NTBC Study.
; Alvarez F; Atkinson S; Bouchard M; Brunel-Guitton C; Buhas D; Bussières JF; Dubois J; Fenyves D; Goodyer P; Gosselin M; Halac U; Labbé P; Laframboise R; Maranda B; Melançon S; Merouani A; Mitchell GA; Mitchell J; Parizeault G; Pelletier L; Phan V; Turcotte JF
Adv Exp Med Biol; 2017; 959():187-195. PubMed ID: 28755196
[TBL] [Abstract][Full Text] [Related]
3. Hereditary Tyrosinemia Type 1 in Turkey.
Aktuglu-Zeybek AC; Kiykim E; Cansever MS
Adv Exp Med Biol; 2017; 959():157-172. PubMed ID: 28755194
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1.
Morrow G; Tanguay RM
Adv Exp Med Biol; 2017; 959():9-21. PubMed ID: 28755181
[TBL] [Abstract][Full Text] [Related]
5. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec.
Larochelle J; Alvarez F; Bussières JF; Chevalier I; Dallaire L; Dubois J; Faucher F; Fenyves D; Goodyer P; Grenier A; Holme E; Laframboise R; Lambert M; Lindstedt S; Maranda B; Melançon S; Merouani A; Mitchell J; Parizeault G; Pelletier L; Phan V; Rinaldo P; Scott CR; Scriver C; Mitchell GA
Mol Genet Metab; 2012 Sep; 107(1-2):49-54. PubMed ID: 22885033
[TBL] [Abstract][Full Text] [Related]
6. NTBC and Correction of Renal Dysfunction.
Maiorana A; Dionisi-Vici C
Adv Exp Med Biol; 2017; 959():93-100. PubMed ID: 28755187
[TBL] [Abstract][Full Text] [Related]
7. Molecular Pathogenesis of Liver Injury in Hereditary Tyrosinemia 1.
Tanguay RM; Angileri F; Vogel A
Adv Exp Med Biol; 2017; 959():49-64. PubMed ID: 28755183
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1.
Langlois C; Jorquera R; Finegold M; Shroads AL; Stacpoole PW; Tanguay RM
Biochem Pharmacol; 2006 May; 71(11):1648-61. PubMed ID: 16581029
[TBL] [Abstract][Full Text] [Related]
9. Kidneys of mice with hereditary tyrosinemia type I are extremely sensitive to cytotoxicity.
Jacobs SM; van Beurden DH; Klomp LW; Berger R; van den Berg IE
Pediatr Res; 2006 Mar; 59(3):365-70. PubMed ID: 16492973
[TBL] [Abstract][Full Text] [Related]
10. Liver Cancer in Tyrosinemia Type 1.
van Ginkel WG; Pennings JP; van Spronsen FJ
Adv Exp Med Biol; 2017; 959():101-109. PubMed ID: 28755188
[TBL] [Abstract][Full Text] [Related]
11. [Clinical follow up of Chilean patients with tyrosinemia type 1 treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-ciclohexanedione (NTBC)].
Raimann E; Cornejo V; Arias C; Cabello JF; Castro G; Fernández E; de la Parra A
Rev Med Chil; 2012 Feb; 140(2):169-75. PubMed ID: 22739945
[TBL] [Abstract][Full Text] [Related]
12. Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1.
Li L; Zhang Q; Yang H; Zou Q; Lai C; Jiang F; Zhao P; Luo Z; Yang J; Chen Q; Wang Y; Newsome PN; Frampton J; Maxwell PH; Li W; Chen S; Wang D; Siu TS; Tam S; Tse HF; Qin B; Bao X; Esteban MA; Lai L
J Biol Chem; 2017 Mar; 292(11):4755-4763. PubMed ID: 28053091
[TBL] [Abstract][Full Text] [Related]
13. Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model.
Orejuela D; Jorquera R; Bergeron A; Finegold MJ; Tanguay RM
J Hepatol; 2008 Feb; 48(2):308-17. PubMed ID: 18093685
[TBL] [Abstract][Full Text] [Related]
14. Renal proximal tubular cells acquire resistance to cell death stimuli in mice with hereditary tyrosinemia type 1.
Luijerink MC; van Beurden EA; Malingré HE; Jacobs SM; Grompe M; Klomp LW; Berger R; van den Berg IE
Kidney Int; 2004 Sep; 66(3):990-1000. PubMed ID: 15327392
[TBL] [Abstract][Full Text] [Related]
15. Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.
Colemonts-Vroninks H; Neuckermans J; Marcelis L; Claes P; Branson S; Casimir G; Goyens P; Martens GA; Vanhaecke T; De Kock J
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375092
[TBL] [Abstract][Full Text] [Related]
16. A Lithuanian Case of Tyrosinemia Type 1 with a Literature Review: A Rare Cause of Acute Liver Failure in Childhood.
Rokaitė R; Čibirkaitė A; Zeleckytė V; Lazdinytė G; Dženkaitis M
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256395
[TBL] [Abstract][Full Text] [Related]
17. Tyrosinemia and Liver Transplantation: Experience at CHU Sainte-Justine.
Alvarez F; Mitchell GA
Adv Exp Med Biol; 2017; 959():67-73. PubMed ID: 28755184
[TBL] [Abstract][Full Text] [Related]
18. Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain.
Couce ML; Sánchez-Pintos P; Aldámiz-Echevarría L; Vitoria I; Navas V; Martín-Hernández E; García-Volpe C; Pintos G; Peña-Quintana L; Hernández T; Gil D; Sánchez-Valverde F; Bueno M; Roca I; López-Ruzafa E; Díaz-Fernández C
Medicine (Baltimore); 2019 Sep; 98(39):e17303. PubMed ID: 31574857
[TBL] [Abstract][Full Text] [Related]
19. Tyrosinemia Type I in Japan: A Report of Five Cases.
Nakamura K; Ito M; Shigematsu Y; Endo F
Adv Exp Med Biol; 2017; 959():133-138. PubMed ID: 28755191
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.
van Ginkel WG; Rodenburg IL; Harding CO; Hollak CEM; Heiner-Fokkema MR; van Spronsen FJ
Paediatr Drugs; 2019 Dec; 21(6):413-426. PubMed ID: 31667718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
